Literature DB >> 32054379

Inevitable role of TGF-β1 in progression of nonalcoholic fatty liver disease.

Bhagyalakshmi Nair1, Lekshmi R Nath1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a major health concern and the most commonly diagnosed chronic liver manifestation among 25% worldwide population. Obesity, insulin resistance, accumulation of toxic lipid free radicals, generation of oxidative stress, overconsumption of fat containing dietary meals and lack of exercise are the paramount factors accountable for the development of NAFLD. During NAFLD, increased oxidative stress and production of enormous number of toxic free radicals activates a number of pro-inflammatory and inflammatory pathways. TGF-β signaling mechanisms play a central role in maintaining the normal homeostasis of liver. TGF-β1, one of the three isoforms of TGF-β family has significant role in different stages of chronic liver conditions. TGF-β1 promotes HSC activation and extracellular matrix production (ECM), which further contributes in the progression of NAFLD. In this review, we outline the role of TGF-β1 in different phases of progressive NAFLD along with the signaling mechanism.

Entities:  

Keywords:  HSC activation; Nonalcoholic fatty liver disease; TGF-β1; inflammation

Mesh:

Substances:

Year:  2020        PMID: 32054379     DOI: 10.1080/10799893.2020.1726952

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  10 in total

1.  Effects of Different Green Teas on Obesity and Non-Alcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice.

Authors:  Dan-Dan Zhou; Qian-Qian Mao; Bang-Yan Li; Adila Saimaiti; Si-Yu Huang; Ruo-Gu Xiong; Ao Shang; Min Luo; Hang-Yu Li; Ren-You Gan; Hua-Bin Li; Sha Li
Journal:  Front Nutr       Date:  2022-06-24

2.  Heightened Plasma Levels of Transforming Growth Factor Beta (TGF-β) and Increased Degree of Systemic Biochemical Perturbation Characterizes Hepatic Steatosis in Overweight Pediatric Patients: A Cross-Sectional Study.

Authors:  Junaura R Barretto; Ney Boa-Sorte; Caian L Vinhaes; Hayna Malta-Santos; Jessica Rebouças-Silva; Camila F Ramos; Monica A S Torres-Nascimento; Valeria M Borges; Bruno B Andrade
Journal:  Nutrients       Date:  2020-06-02       Impact factor: 5.717

3.  Lrp6 Genotype affects Individual Susceptibility to Nonalcoholic Fatty Liver Disease and Silibinin Therapeutic Response via Wnt/β-catenin-Cyp2e1 Signaling.

Authors:  Li-Jie Chen; Xiu-Xian Lin; Jing Guo; Ying Xu; Song-Xia Zhang; Dan Chen; Qing Zhao; Jian Xiao; Guang-Hui Lian; Shi-Fang Peng; Dong Guo; Hong Yang; Yan Shu; Hong-Hao Zhou; Wei Zhang; Yao Chen
Journal:  Int J Biol Sci       Date:  2021-09-21       Impact factor: 6.580

4.  Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro.

Authors:  Jingquan Ji; Ming Feng; Yan Huang; Xiaohong Niu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

5.  Intervention Study of Dictyophora Polysaccharides on Arsenic-Induced Liver Fibrosis in SD Rats.

Authors:  Guoze Wang; Peipei Zuo; Kai Ding; Qibing Zeng; Ting Hu; Shaofeng Wei; Peng Luo
Journal:  Biomed Res Int       Date:  2022-03-30       Impact factor: 3.411

6.  Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation.

Authors:  Ying Wang; Chaojie Chen; Jiajun Chen; Tingting Sang; He Peng; Xiaojian Lin; Qian Zhao; Shengjia Chen; Thomas Eling; Xingya Wang
Journal:  Redox Biol       Date:  2022-04-27       Impact factor: 10.787

Review 7.  Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma.

Authors:  Aswathy R Devan; Keechilat Pavithran; Bhagyalakshmi Nair; Maneesha Murali; Lekshmi R Nath
Journal:  World J Gastroenterol       Date:  2022-09-28       Impact factor: 5.374

8.  Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4.

Authors:  Khaoula Errafii; Neyla S Al-Akl; Olfa Khalifa; Abdelilah Arredouani
Journal:  J Transl Med       Date:  2021-06-02       Impact factor: 5.531

9.  Potential therapeutic targets and biological mechanisms of Centella asiatica on hepatic fibrosis: a study of network pharmacology.

Authors:  Yuli Fan; Xiaoyan Yin
Journal:  Ann Transl Med       Date:  2021-06

Review 10.  Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis-Roles as Putative Treatment Targets?

Authors:  Alexandra Zisser; David H Ipsen; Pernille Tveden-Nyborg
Journal:  Biomedicines       Date:  2021-03-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.